| Code | CSB-RA858415MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Setrusumab, targeting sclerostin (SOST), a glycoprotein secreted primarily by osteocytes that functions as a key negative regulator of bone formation. SOST inhibits the Wnt signaling pathway by binding to LRP5/6 co-receptors, thereby suppressing osteoblast differentiation and activity. Elevated sclerostin levels are associated with reduced bone mineral density and increased fracture risk, making it a critical target in osteoporosis research. Loss-of-function mutations in the SOST gene cause sclerosteosis and van Buchem disease, rare conditions characterized by excessive bone formation that validate its role in skeletal homeostasis.
Setrusumab represents an anti-sclerostin therapeutic antibody designed to enhance bone formation by neutralizing SOST activity and restoring Wnt signaling in bone tissue. This biosimilar provides researchers with a valuable tool for investigating sclerostin biology, bone metabolism pathways, and potential therapeutic mechanisms in metabolic bone diseases. It enables studies examining osteoblast function, bone remodeling dynamics, and the interplay between sclerostin and other skeletal regulatory factors.
There are currently no reviews for this product.